Wuhan Shumi Brain Science & Technology Co., Ltd.

Wuhan Shumi Brain Science & Technology Co., Ltd. is dedicated to developing viral vector technology, integrating cutting-edge technologies such as gene editing and stem cells, to provide full-system viral vector research tools, custom vector development and preparation, and overall project research services for basic research and translational medicine in the fields of neuroscience, stem cell therapy, oncology, immunology, metabolism, gene therapy, and more. For corporate clients in the above fields, the company provides large-scale clinical-grade viral vector preparation, viral vector development for oncolytic viruses and tumor immunocellular therapy, as well as gene therapy drug development and preparation, and central nervous system disease efficacy evaluation services. The company is headquartered in Zhongke Kaiwu Industrial Park, East Lake High-tech Development Zone, Wuhan, with a total area of 1,700 square meters, including approximately 800 square meters of laboratory space. It currently has more than 240 employees, of whom approximately 180 are technical personnel, and approximately 90 hold doctoral or master's degrees. The company has developed six major viral technology platforms, including adeno-associated virus, lentivirus, rabies virus, pseudorabies virus, herpes simplex virus, and vesicular stomatitis virus, and has established technology platforms related to stem cells, gene editing, and tumor research. It possesses a complete biological experimental platform, including molecular, cellular, biochemical, viral vector preparation, and biosafety level 2 laboratories, as well as animal experimental platforms and animal physiology, behavioral, and optical analysis platforms. Currently, it serves more than 400 national laboratories, hospitals, and corporate clients in China, is a technical support unit for national key laboratories, and has established cooperative relationships with many laboratories, central hospitals, and drug research institutions across the country. In 2018, it was awarded the title of National High-tech Enterprise, and received honors such as the Optics Valley "3551" Talent Project and Wuhan Science and Technology Little Giant. At present, the company has established branch offices including the Wuhan headquarters, Beijing office, Shanghai office, and Guangzhou office. Due to development needs, the company is recruiting mid-to-senior level research, sales, and management talents, and warmly welcomes like-minded outstanding talents to join the team! Business scope: I. Scientific research services: (1) Off-the-shelf products: more than 2,000 viral vector tools and more than 30 gene-modified neural stem cell products; (2) Custom services: design and custom services for adeno-associated virus, lentivirus, and retrovirus using technologies such as gene expression, gene interference, and gene editing; vector cloning and cell line preparation services; (3) Integrated services: providing overall experimental services for basic research and translational medicine in neural circuits, gene editing, oncology, stem cells, exosomes, gene function, and efficacy research, including research protocol justification and design, experimental project implementation, and result organization and analysis services in molecular, viral, biochemical, cellular, and animal experiments; II. Corporate services: (1) Large-scale clinical-grade adeno-associated AAV virus and lentiviral vector preparation; (2) viral vector development for oncolytic viruses and tumor immunocellular therapy, and anti-tumor efficacy evaluation services; (3) gene therapy drug development, preparation, and efficacy evaluation services; (4) central nervous system disease efficacy evaluation services;